Published in Blood on July 13, 2015
Matrine induces Akt/mTOR signalling inhibition-mediated autophagy and apoptosis in acute myeloid leukaemia cells. J Cell Mol Med (2016) 0.78
Stem and progenitor cell alterations in myelodysplastic syndromes. Blood (2017) 0.75
Bardoxolone Methyl and a Related Triterpenoid Downregulate cMyc Expression in Leukemia Cells. Mol Pharmacol (2017) 0.75
Cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation. Blood (2017) 0.75
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature (1994) 21.59
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
p21-activated kinases in cancer. Nat Rev Cancer (2006) 4.24
An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol (2008) 3.94
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood (2005) 3.22
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest (2010) 2.96
Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem (2000) 2.51
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia (2010) 2.30
PAK signalling during the development and progression of cancer. Nat Rev Cancer (2014) 2.21
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer (2008) 2.01
Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells. Mol Cell Biol (2004) 1.96
c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood (2005) 1.96
The proto-oncogene c-myc in hematopoietic development and leukemogenesis. Oncogene (2002) 1.85
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma. J Natl Cancer Inst (2013) 1.68
Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol (2003) 1.51
Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene (2007) 1.43
Regulation of Akt/PKB activity by P21-activated kinase in cardiomyocytes. J Mol Cell Cardiol (2007) 1.38
p21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res (2012) 1.32
Identification of novel Myc target genes with a potential role in lymphomagenesis. Nucleic Acids Res (2004) 1.20
Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion. Int J Cancer (2010) 1.19
H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. Cancer Cell (2012) 1.19
P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res (2007) 1.17
Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. Am J Physiol Heart Circ Physiol (2011) 1.10
MYC/MAX control ERK signaling and pluripotency by regulation of dual-specificity phosphatases 2 and 7. Genes Dev (2013) 1.04
P-21 activated kinase 1 knockdown inhibits β-catenin signalling and blocks colorectal cancer growth. Cancer Lett (2011) 0.97
P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer. J Urol (2007) 0.96
PAK1-Nck regulates cyclin D1 promoter activity in response to prolactin. Mol Endocrinol (2011) 0.94
What retroviruses teach us about the involvement of c-Myc in leukemias and lymphomas. Leukemia (2002) 0.87
Genomic alterations in blastic natural killer/extranodal natural killer-like T cell lymphoma with cutaneous involvement. J Invest Dermatol (2003) 0.84
Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis. Cell Rep (2014) 0.84
Cooperation of Myb and Myc proteins in T cell lymphomagenesis. Oncogene (1999) 0.83